Menu
Back to Journals » Drug, Healthcare and Patient Safety » Volume 2
Safety and clinical efficacy of golimumab in the treatment of arthritides
Published 28 September 2010 Volume 2010:2 Pages 169—180
DOI https://doi.org/10.2147/DHPS.S6187
Review by Single anonymous peer review
Peer reviewer comments 2
Ismail Simsek, Yusuf Yazici
New York University School of Medicine, NYU Hospital for Joint Diseases, New York, USA
Abstract: Golimumab is a human anti-tumor necrosis factor (TNF)-alpha monoclonal antibody that was recently approved for the treatment of patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. This review covers the published clinical trial data on the use of golimumab for the approved indications mentioned above with respect to efficacy and safety. The various ongoing trials for golimumab have yielded promising results in terms of efficacy and safety in methotrexate-naive and -resistant patients with rheumatoid arthritis, as well as in patients who were previously treated with other anti-TNF agents. In addition, the efficacy of golimumab in psoriatic arthritis and ankylosing spondylitis has also been demonstrated. The real safety information will be available only once the drug has been used in many more patients, who frequently have comorbid conditions.
Keywords: arthritis, rheumatoid, psoriatic arthritis, ankylosing spondylitis
© 2010 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.
By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.